44.2% had ≤3months of treatment, and 55.8% had N3months of treatment. Older patients were less likely to receive chemotherapy, while those with higher stage and grade were more likely to receive chemotherapy (P b 0.05 for all). Among high-risk patients, the duration of chemotherapy did not impact overall (HR = 0.93, 95% CI, 0.67–1.27) or cancer specific (HR = 0.93; 95% CI, 0.61–1.42) survival.